These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 23312691)
1. Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus. Shiau S; Arpadi S; Strehlau R; Martens L; Patel F; Coovadia A; Abrams EJ; Kuhn L J Pediatr; 2013 Jun; 162(6):1138-45, 1145.e1-2. PubMed ID: 23312691 [TBL] [Abstract][Full Text] [Related]
2. Growth Recovery Among HIV-infected Children Randomized to Lopinavir/Ritonavir or NNRTI-based Antiretroviral Therapy. Achan J; Kakuru A; Ikilezi G; Mwangwa F; Plenty A; Charlebois E; Young S; Havlir D; Kamya M; Ruel T Pediatr Infect Dis J; 2016 Dec; 35(12):1329-1332. PubMed ID: 27580060 [TBL] [Abstract][Full Text] [Related]
3. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425 [TBL] [Abstract][Full Text] [Related]
4. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arpadi S; Shiau S; Strehlau R; Martens L; Patel F; Coovadia A; Abrams EJ; Kuhn L Arch Dis Child; 2013 Apr; 98(4):258-64. PubMed ID: 23220209 [TBL] [Abstract][Full Text] [Related]
6. A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa. Cassim H; Otwombe K; Lazarus E; Liberty A; Gray GE; Greeff OBW; Violari A PLoS One; 2017; 12(7):e0180645. PubMed ID: 28686654 [TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa. Okomo U; Togun T; Oko F; Peterson K; Townend J; Peterson I; Jaye A BMC Pediatr; 2012 Jul; 12():95. PubMed ID: 22770231 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982 [TBL] [Abstract][Full Text] [Related]
9. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial. Coovadia A; Abrams EJ; Strehlau R; Shiau S; Pinillos F; Martens L; Patel F; Hunt G; Tsai WY; Kuhn L JAMA; 2015 Nov; 314(17):1808-17. PubMed ID: 26529159 [TBL] [Abstract][Full Text] [Related]
10. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. Coovadia A; Abrams EJ; Stehlau R; Meyers T; Martens L; Sherman G; Hunt G; Hu CC; Tsai WY; Morris L; Kuhn L JAMA; 2010 Sep; 304(10):1082-90. PubMed ID: 20823434 [TBL] [Abstract][Full Text] [Related]
11. Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial. Blanche S; Tylleskär T; Peries M; Kankasa C; Engebretsen I; Meda N; Tumwine JK; Singata-Madliki M; Mwiya M; Van de Perre P; Nagot N; Lancet HIV; 2019 May; 6(5):e307-e314. PubMed ID: 30814028 [TBL] [Abstract][Full Text] [Related]
12. HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa. Teasdale CA; Sogaula N; Yuengling KA; Wang C; Mutiti A; Arpadi S; Nxele M; Pepeta L; Mogashoa M; Rivadeneira ED; Abrams EJ J Int AIDS Soc; 2018 Aug; 21(8):e25168. PubMed ID: 30094952 [TBL] [Abstract][Full Text] [Related]
13. Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. Lindsey JC; Hughes MD; Violari A; Eshleman SH; Abrams EJ; Bwakura-Dangarembizi M; Barlow-Mosha L; Kamthunzi P; Sambo PM; Cotton MF; Moultrie H; Khadse S; Schimana W; Bobat R; Zimmer B; Petzold E; Mofenson LM; Jean-Philippe P; Palumbo P; Pediatr Infect Dis J; 2014 Aug; 33(8):846-54. PubMed ID: 25222305 [TBL] [Abstract][Full Text] [Related]
14. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. Reitz C; Coovadia A; Ko S; Meyers T; Strehlau R; Sherman G; Kuhn L; Abrams EJ J Infect Dis; 2010 Apr; 201(8):1121-31. PubMed ID: 20214476 [TBL] [Abstract][Full Text] [Related]
15. First-line antiretroviral drug discontinuations in children. Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529 [TBL] [Abstract][Full Text] [Related]
16. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. Barlow-Mosha L; Angelidou K; Lindsey J; Archary M; Cotton M; Dittmer S; Fairlie L; Kabugho E; Kamthunzi P; Kinikar A; Mbengeranwa T; Msuya L; Sambo P; Patel K; Barr E; Jean-Phillipe P; Violari A; Mofenson L; Palumbo P; Chi BH Clin Infect Dis; 2016 Oct; 63(8):1113-1121. PubMed ID: 27439527 [TBL] [Abstract][Full Text] [Related]
17. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial. Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V; BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406 [TBL] [Abstract][Full Text] [Related]
18. Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort. Amani-Bosse C; Dahourou DL; Malateste K; Amorissani-Folquet M; Coulibaly M; Dattez S; Emieme A; Barry M; Rouzioux C; N'gbeche S; Yonaba C; Timité-Konan M; Mea V; Ouédraogo S; Blanche S; Meda N; Seguin-Devaux C; Leroy V J Int AIDS Soc; 2017 Apr; 20(1):21362. PubMed ID: 28453240 [TBL] [Abstract][Full Text] [Related]
19. Growth trajectories of breastfed HIV-exposed uninfected and HIV-unexposed children under conditions of universal maternal antiretroviral therapy: a prospective study. le Roux SM; Abrams EJ; Donald KA; Brittain K; Phillips TK; Nguyen KK; Zerbe A; Kroon M; Myer L Lancet Child Adolesc Health; 2019 Apr; 3(4):234-244. PubMed ID: 30773459 [TBL] [Abstract][Full Text] [Related]
20. Optimization of antiretroviral therapy in HIV-infected children under 3 years of age: a systematic review. Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams EJ AIDS; 2014 Mar; 28 Suppl 2():S137-46. PubMed ID: 24849473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]